UNSPSC 51422208: Flunarizine hydrochloride

This classification denotes a histamine-1 receptor antagonist and calcium channel blocker with the molecular formula C26H26F2N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C11102TO53, chemically known as (e)-1-(bis-(p-fluorophenyl)methyl)-4-cinnamylpiperazine dihydrochloride, but more generally known as flunarizine hydrochloride, which bears US NIH Compound Identifier 5282407.

UNSPSC 51422208 Flunarizine hydrochloride is a Commodity code that maps to pharmaceutical product procurement, though recent state and local opportunities posted under this code show substantial scope misalignment. The Seminole County, Florida solicitation targets naloxone and drug deactivation systems rather than flunarizine, and the Texas Health and Human Services Commission RFI addresses direct-to-manufacturer prescription program infrastructure rather than any specific pharmaceutical product. State and local governments using this code are primarily health and human services agencies—county health departments and state pharmacy benefit programs—seeking to procure or coordinate delivery of pharmaceutical products and related dispensing systems for public health and social services missions. The work involves bulk procurement of finished pharmaceutical products with defined unit pricing, quarterly or as-needed delivery logistics, compliance with federal funding requirements when FEMA or state general revenue funds the purchase, and vendor insurance and employment verification.

Recent activity appears concentrated in Florida and Texas, with Seminole County posting an IFB for naloxone and deactivation systems with a response deadline of July 26, 2023, requiring 1,900 units of naloxone and 800 deactivation systems annually to a single county health facility, and the Texas HHS Commission issuing an RFI on April 3, 2026, to gather vendor intelligence on direct-to-manufacturer prescription fulfillment models for state employee and agency health plans. The code shows limited recent posting activity overall, and the mismatch between the nominal flunarizine scope and the actual solicitations—naloxone being a distinct opioid antagonist, not a calcium channel blocker—signals either inconsistent code assignment by issuing bodies or a broader pharmaceutical-commodity miscoding issue in state and local systems. Firms pursuing this code should verify the actual drug or product category before investing bid preparation effort.